Pasar al contenido principal

ACTIVADORES FARMACOLOGICOS DE PP2A/B55A CON POTENCIAL EN PATOLOGIAS VASCULARES

PID2023-148340OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2023
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE CORDOBA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Helvia. Repositorio Institucional de la Universidad de Córdoba
Publicación Artículo científico (JournalArticle)

Cannabidiol improves metabolic profiles and alleviates liver inflammation and fibrosis in conditions of androgenic obesity and polycystic ovary syndrome

Helvia. Repositorio Institucional de la Universidad de Córdoba
Publicación Artículo científico (JournalArticle)

Etrinabdione (VCE-004.8), a B55α activator, promotes angiogenesis and arteriogenesis in critical limb ischemia

  • García-Martín, Adela
  • Prados, María E.
  • Lastres-Cubillo, Isabel
  • Ponce-Díaz, Francisco
  • Cerero Tejero, Laura
  • Garrido Rodríguez-Córdoba, Martín
  • Navarrete, Carmen
  • Pineda, Rafael
  • Rodríguez, Ana B.
  • Muñoz, Ignacio
  • Moya González, Javier
  • Medeot, Antonella
  • Moreno Moreno, José Antonio
  • Chacón, Antonio
  • García-Revillo García, José
  • Muñoz, Eduardo
Background: Vasculogenic therapies explored for the treatment of peripheral artery disease (PAD) have encountered minimal success in clinical trials. Addressing this, B55α, an isoform of protein phosphatase 2A (PP2A), emerges as pivotal in vessel remodeling through activation of hypoxia-inducible factor 1α (HIF-1α). This study delves into the pharmacological profile of VCE-004.8 (Etrinabdione) and evaluates its efficacy in a preclinical model of critical limb ischemia, with a focus on its potential as a PP2A/B55α activator to induce angiogenesis and arteriogenesis. Methods: Vascular endothelial cells were used for in vitro experiments. Aorta ring assay was performed to explore sprouting activity. Matrigel plug-in assay was used to assess the angiogenic potential. Critical limb ischemia (CLI) in mice was induced by double ligation in the femoral arteria. Endothelial vascular and fibrotic biomarkers were studied by immunohistochemistry and qPCR. Arteriogenesis was investigated by microvascular casting and micro-CT. Proteomic analysis in vascular tissues was analyzed by LC–MS/MS. Ex-vivo expression of B55α and biomarkers were investigated in artery samples from PAD patients. Results: VCE-004.8 exhibited the ability to induce B55α expression and activate the intersecting pathways B55α/ AMPK/Sirtuin 1/eNOS and B55α/PHD2/HIF-1α. VCE-004.8 prevented OxLDL and H2O2- induced cytotoxicity, senescence, and inflammation in endothelial cells. Oral VCE-004.8 increased aorta sprouting in vitro and angiogenesis in vivo. In CLI mice VCE-004.8 improved collateral vessel formation and induced endothelial cells proliferation, angiogenic gene expression and prevented fibrosis. The expression of B55α, Caveolin 1 and Sirtuin-1 is reduced in arteries from CLI mice and PAD patient, and the expression of these markers was restored in mice treated with VCE-004.8. Conclusions: The findings presented in this study indicate that Etrinabdione holds promise in mitigating endothelial cell damage and senescence, while concurrently fostering arteriogenesis and angiogenesis. These observations position Etrinabdione as a compelling candidate for the treatment of PAD, and potentially other cardiovascular disorders.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Discovery and pharmacological evaluation of a novel series of chromenopyrazole-based GPR55 modulators in an androgen-driven model of female metabolic dysfunction

  • Ponce-Díaz, Francisco J.
  • Ruiz-Pino, Francisco
  • Herraiz, Aitor
  • Romero, Beatriz
  • Cerero-Tejero, Laura
  • García-Martín, Adela
  • Porzio-Gonzalez, Simon
  • Morales, Paula
  • Sánchez-Garrido, Miguel A.
  • Pulido, Marina R.
  • Jagerovic, Nadine
  • Tena-Sempere, Manuel
  • Muñoz, Eduardo
GPR55 is a lipid-responsive G-protein-coupled receptor implicated in metabolic regulation, but its characterization has been limited by the poor selectivity and pathway bias of classical ligands. To obtain more reliable chemical tools, we revisited the chromenopyrazole scaffold and prepared a focused series of derivatives to refine GPR55 pharmacology. In vitro profiling identified compound A as a selective lysophosphatidylinositol (LPI)-dependent positive allosteric modulator, whereas compounds 16 and 23 displayed dual orthosteric/allosteric activity. All derivatives showed clean GPR55 engagement with no detectable cannabinoid receptor type 2 activity, highlighting the improved selectivity of this scaffold., The biological relevance of these pharmacological profiles was assessed in a preclinical model of androgen-driven metabolic dysfunction reproducing key features of the metabolic phenotype observed in women with polycystic ovary syndrome (PCOS). In this model, compound A improved body weight regulation, glucose tolerance, and insulin sensitivity, while lowering serum cholesterol and triglycerides. Hepatic parameters followed a similar pattern, with reduced steatosis, macrophage infiltration, and early fibrotic remodeling. Compounds 16 and 23 produced broadly comparable benefits despite their distinct modes of GPR55 engagement, suggesting convergence on shared downstream pathways buffering metabolic stress. Hepatic GPR55 expression increased under steatotic and inflammatory conditions but normalized after treatment, supporting the potential advantage of allosteric enhancement of endogenous LPI signaling., Overall, these findings identify chromenopyrazoles as a selective GPR55-modulating scaffold with the potential to mitigate metabolic and hepatic dysfunction in models reflecting key features of PCOS., This work was supported by grants PID2023-149244NB-I00 (to MTS), PID2023-148340OB-I00 (to EM), and PID2022-1127833OB-100 (to NJ) from the Agencia Estatal de Investigación, Spain; co-funded with EU funds from FEDER Program, and EU research contract GAP-101080219 (eprObes; funded by the European Union through the Horizon Europe Framework Programme). CIBER Fisiopatología de la Obesidad y Nutrición is an initiative of Instituto de Salud Carlos III, Spain., Peer reviewed